Annual CFO
-$5.74 M
+$68.02 M+92.21%
31 December 2023
Summary:
Rigel Pharmaceuticals annual cash flow from operations is currently -$5.74 million, with the most recent change of +$68.02 million (+92.21%) on 31 December 2023. During the last 3 years, it has risen by +$46.44 million (+88.99%). RIGL annual CFO is now -112.29% below its all-time high of $46.74 million, reached on 31 December 2010.RIGL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$21.68 M
+$21.38 M+7078.48%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly cash flow from operations is currently $21.68 million, with the most recent change of +$21.38 million (+7078.48%) on 30 September 2024. Over the past year, it has increased by +$23.04 million (+1695.22%). RIGL quarterly CFO is now -72.41% below its all-time high of $78.58 million, reached on 30 June 2010.RIGL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$10.73 M
+$23.04 M+187.15%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM cash flow from operations is currently $10.73 million, with the most recent change of +$23.04 million (+187.15%) on 30 September 2024. Over the past year, it has increased by +$32.14 million (+150.10%). RIGL TTM CFO is now -78.14% below its all-time high of $49.07 million, reached on 31 March 2011.RIGL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +92.2% | +1695.2% | +150.1% |
| 3 y3 years | +89.0% | +310.5% | +14.2% |
| 5 y5 years | +90.2% | +248.1% | +153.1% |
RIGL Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -197.7% | +92.2% | at high | +184.6% | at high | +114.5% |
| 5 y | 5 years | -197.7% | +92.2% | -60.7% | +184.6% | at high | +114.5% |
| alltime | all time | -112.3% | +94.5% | -72.4% | +174.6% | -78.1% | +110.1% |
Rigel Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $21.68 M(+7078.5%) | $10.73 M(-187.1%) |
| June 2024 | - | $302.00 K(-106.0%) | -$12.31 M(+84.2%) |
| Mar 2024 | - | -$5.01 M(-19.7%) | -$6.68 M(+16.4%) |
| Dec 2023 | -$5.74 M(-92.2%) | -$6.24 M(+359.2%) | -$5.74 M(-73.2%) |
| Sept 2023 | - | -$1.36 M(-122.9%) | -$21.41 M(-35.8%) |
| June 2023 | - | $5.93 M(-245.6%) | -$33.35 M(-36.1%) |
| Mar 2023 | - | -$4.07 M(-81.4%) | -$52.20 M(-29.2%) |
| Dec 2022 | -$73.76 M(-1354.8%) | -$21.91 M(+64.7%) | -$73.76 M(+4.0%) |
| Sept 2022 | - | -$13.30 M(+3.0%) | -$70.94 M(+4.4%) |
| June 2022 | - | -$12.91 M(-49.6%) | -$67.93 M(<-9900.0%) |
| Mar 2022 | - | -$25.64 M(+34.3%) | $196.00 K(-96.7%) |
| Dec 2021 | $5.88 M(-111.3%) | -$19.09 M(+85.4%) | $5.88 M(-37.4%) |
| Sept 2021 | - | -$10.30 M(-118.6%) | $9.39 M(+4437.2%) |
| June 2021 | - | $55.22 M(-376.7%) | $207.00 K(-100.3%) |
| Mar 2021 | - | -$19.95 M(+28.1%) | -$69.05 M(+32.3%) |
| Dec 2020 | -$52.19 M(+25.7%) | -$15.57 M(-20.1%) | -$52.19 M(+12.8%) |
| Sept 2020 | - | -$19.48 M(+38.8%) | -$46.26 M(+11.7%) |
| June 2020 | - | -$14.04 M(+353.9%) | -$41.42 M(-5.9%) |
| Mar 2020 | - | -$3.09 M(-67.9%) | -$44.03 M(+6.1%) |
| Dec 2019 | -$41.51 M(-29.4%) | -$9.65 M(-34.1%) | -$41.51 M(+105.3%) |
| Sept 2019 | - | -$14.64 M(-12.1%) | -$20.22 M(-21.2%) |
| June 2019 | - | -$16.65 M(+2826.4%) | -$25.66 M(-28.7%) |
| Mar 2019 | - | -$569.00 K(-104.9%) | -$36.00 M(-38.8%) |
| Dec 2018 | -$58.83 M(-24.2%) | $11.64 M(-158.0%) | -$58.83 M(-34.8%) |
| Sept 2018 | - | -$20.08 M(-25.6%) | -$90.19 M(+2.8%) |
| June 2018 | - | -$26.99 M(+15.4%) | -$87.71 M(+9.4%) |
| Mar 2018 | - | -$23.39 M(+18.7%) | -$80.19 M(+3.4%) |
| Dec 2017 | -$77.56 M(+2.2%) | -$19.71 M(+12.0%) | -$77.56 M(+10.3%) |
| Sept 2017 | - | -$17.61 M(-9.6%) | -$70.31 M(-6.6%) |
| June 2017 | - | -$19.47 M(-6.2%) | -$75.27 M(+1.4%) |
| Mar 2017 | - | -$20.76 M(+66.6%) | -$74.23 M(-2.2%) |
| Dec 2016 | -$75.89 M(+224.1%) | -$12.46 M(-44.8%) | -$75.89 M(-1.7%) |
| Sept 2016 | - | -$22.57 M(+22.4%) | -$77.22 M(+20.5%) |
| June 2016 | - | -$18.43 M(-17.8%) | -$64.11 M(+0.5%) |
| Mar 2016 | - | -$22.42 M(+62.5%) | -$63.82 M(+172.6%) |
| Dec 2015 | -$23.41 M(-66.4%) | -$13.80 M(+45.9%) | -$23.41 M(-4.9%) |
| Sept 2015 | - | -$9.46 M(-47.9%) | -$24.62 M(-26.6%) |
| June 2015 | - | -$18.15 M(-200.9%) | -$33.54 M(-5.1%) |
| Mar 2015 | - | $17.99 M(-219.9%) | -$35.34 M(-49.3%) |
| Dec 2014 | -$69.75 M(-19.0%) | -$15.00 M(-18.4%) | -$69.75 M(-5.3%) |
| Sept 2014 | - | -$18.38 M(-7.9%) | -$73.65 M(-3.1%) |
| June 2014 | - | -$19.94 M(+21.4%) | -$76.02 M(-1.8%) |
| Mar 2014 | - | -$16.43 M(-13.1%) | -$77.39 M(-10.1%) |
| Dec 2013 | -$86.08 M(+1.0%) | -$18.90 M(-8.9%) | -$86.08 M(-3.0%) |
| Sept 2013 | - | -$20.74 M(-2.7%) | -$88.75 M(+1.3%) |
| June 2013 | - | -$21.32 M(-15.1%) | -$87.63 M(+0.7%) |
| Mar 2013 | - | -$25.11 M(+16.4%) | -$87.05 M(+2.2%) |
| Dec 2012 | -$85.21 M | -$21.57 M(+9.9%) | -$85.21 M(+3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | -$19.63 M(-5.4%) | -$82.29 M(+9.1%) |
| June 2012 | - | -$20.74 M(-10.9%) | -$75.46 M(+5.0%) |
| Mar 2012 | - | -$23.27 M(+24.8%) | -$71.89 M(+3.6%) |
| Dec 2011 | -$69.38 M(-248.4%) | -$18.65 M(+45.8%) | -$69.38 M(+71.5%) |
| Sept 2011 | - | -$12.79 M(-25.5%) | -$40.45 M(-13.3%) |
| June 2011 | - | -$17.16 M(-17.3%) | -$46.67 M(-195.1%) |
| Mar 2011 | - | -$20.76 M(-302.2%) | $49.07 M(+5.0%) |
| Dec 2010 | $46.74 M(-145.5%) | $10.27 M(-154.0%) | $46.74 M(+254.1%) |
| Sept 2010 | - | -$19.01 M(-124.2%) | $13.20 M(+93.5%) |
| June 2010 | - | $78.58 M(-440.3%) | $6.82 M(-107.0%) |
| Mar 2010 | - | -$23.09 M(-0.8%) | -$96.81 M(-5.8%) |
| Dec 2009 | -$102.78 M(-0.7%) | -$23.27 M(-8.3%) | -$102.78 M(-3.6%) |
| Sept 2009 | - | -$25.39 M(+1.3%) | -$106.64 M(+0.8%) |
| June 2009 | - | -$25.06 M(-13.8%) | -$105.79 M(+0.3%) |
| Mar 2009 | - | -$29.06 M(+7.1%) | -$105.50 M(+1.9%) |
| Dec 2008 | -$103.52 M(+98.3%) | -$27.14 M(+10.6%) | -$103.52 M(+22.1%) |
| Sept 2008 | - | -$24.53 M(-1.0%) | -$84.75 M(+14.8%) |
| June 2008 | - | -$24.77 M(-8.5%) | -$73.80 M(+15.6%) |
| Mar 2008 | - | -$27.08 M(+223.3%) | -$63.85 M(+22.3%) |
| Dec 2007 | -$52.21 M(+45.7%) | -$8.38 M(-38.3%) | -$52.21 M(-4.6%) |
| Sept 2007 | - | -$13.58 M(-8.4%) | -$54.72 M(+11.0%) |
| June 2007 | - | -$14.82 M(-4.0%) | -$49.31 M(+19.9%) |
| Mar 2007 | - | -$15.44 M(+41.8%) | -$41.13 M(+14.8%) |
| Dec 2006 | -$35.84 M(+1.9%) | -$10.89 M(+33.3%) | -$35.84 M(+21.7%) |
| Sept 2006 | - | -$8.17 M(+23.1%) | -$29.44 M(-16.0%) |
| June 2006 | - | -$6.64 M(-34.6%) | -$35.05 M(-10.6%) |
| Mar 2006 | - | -$10.14 M(+125.7%) | -$39.22 M(+11.5%) |
| Dec 2005 | -$35.17 M(-7.8%) | -$4.50 M(-67.4%) | -$35.17 M(-2.2%) |
| Sept 2005 | - | -$13.77 M(+27.3%) | -$35.95 M(+7.0%) |
| June 2005 | - | -$10.81 M(+77.4%) | -$33.60 M(-0.2%) |
| Mar 2005 | - | -$6.09 M(+15.5%) | -$33.67 M(-11.8%) |
| Dec 2004 | -$38.15 M(+17.6%) | -$5.28 M(-53.8%) | -$38.15 M(-10.7%) |
| Sept 2004 | - | -$11.42 M(+5.0%) | -$42.73 M(+4.3%) |
| June 2004 | - | -$10.88 M(+2.8%) | -$40.97 M(+5.7%) |
| Mar 2004 | - | -$10.58 M(+7.4%) | -$38.76 M(+19.5%) |
| Dec 2003 | -$32.44 M(-6.0%) | -$9.85 M(+1.9%) | -$32.44 M(-12.8%) |
| Sept 2003 | - | -$9.67 M(+11.6%) | -$37.18 M(+16.9%) |
| June 2003 | - | -$8.66 M(+103.4%) | -$31.81 M(-6.0%) |
| Mar 2003 | - | -$4.26 M(-70.8%) | -$33.84 M(-2.0%) |
| Dec 2002 | -$34.53 M(+116.1%) | -$14.59 M(+239.6%) | -$34.53 M(+50.7%) |
| Sept 2002 | - | -$4.30 M(-59.8%) | -$22.91 M(+7.5%) |
| June 2002 | - | -$10.69 M(+115.8%) | -$21.31 M(+33.0%) |
| Mar 2002 | - | -$4.95 M(+66.4%) | -$16.02 M(+0.2%) |
| Dec 2001 | -$15.98 M(+37.9%) | -$2.98 M(+10.5%) | -$15.98 M(+22.9%) |
| Sept 2001 | - | -$2.69 M(-50.1%) | -$13.01 M(+26.1%) |
| June 2001 | - | -$5.40 M(+9.9%) | -$10.31 M(+109.9%) |
| Mar 2001 | - | -$4.91 M | -$4.91 M |
| Dec 2000 | -$11.59 M(+48.0%) | - | - |
| Dec 1999 | -$7.83 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual CFO year-on-year change?
- What is Rigel Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly CFO year-on-year change?
- What is Rigel Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM CFO year-on-year change?
What is Rigel Pharmaceuticals annual cash flow from operations?
The current annual CFO of RIGL is -$5.74 M
What is the all time high annual CFO for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual cash flow from operations is $46.74 M
What is Rigel Pharmaceuticals annual CFO year-on-year change?
Over the past year, RIGL annual cash flow from operations has changed by +$68.02 M (+92.21%)
What is Rigel Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of RIGL is $21.68 M
What is the all time high quarterly CFO for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly cash flow from operations is $78.58 M
What is Rigel Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, RIGL quarterly cash flow from operations has changed by +$23.04 M (+1695.22%)
What is Rigel Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of RIGL is $10.73 M
What is the all time high TTM CFO for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM cash flow from operations is $49.07 M
What is Rigel Pharmaceuticals TTM CFO year-on-year change?
Over the past year, RIGL TTM cash flow from operations has changed by +$32.14 M (+150.10%)